| 000 | 01446 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250515163910.0 | ||
| 264 | 0 | _c20091009 | |
| 008 | 200910s 0 0 eng d | ||
| 022 | _a1365-2362 | ||
| 024 | 7 |
_a10.1111/j.1365-2362.2009.02108.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWimazal, F | |
| 245 | 0 | 0 |
_aDeferasirox induces regression of iron overload in patients with myelodysplastic syndromes. _h[electronic resource] |
| 260 |
_bEuropean journal of clinical investigation _cMay 2009 |
||
| 300 |
_a406-11 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBenzoates _xtherapeutic use |
| 650 | 0 | 4 | _aDeferasirox |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIron _xanalysis |
| 650 | 0 | 4 |
_aIron Chelating Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aIron Overload _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyelodysplastic Syndromes _xdrug therapy |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTriazoles _xtherapeutic use |
| 700 | 1 | _aNösslinger, T | |
| 700 | 1 | _aBaumgartner, C | |
| 700 | 1 | _aSperr, W R | |
| 700 | 1 | _aPfeilstöcker, M | |
| 700 | 1 | _aValent, P | |
| 773 | 0 |
_tEuropean journal of clinical investigation _gvol. 39 _gno. 5 _gp. 406-11 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2362.2009.02108.x _zAvailable from publisher's website |
| 999 |
_c18757957 _d18757957 |
||